Navigation Links
International HapMap consortium expands mapping effort

The International HapMap Consortium, boosted by an additional $3.3 million in public-private support, today announced plans to create an even more powerful map of human genetic variation than originally envisioned. The map will accelerate the discovery of genes related to common diseases, such as asthma, cancer, diabetes and heart disease.

When the project was launched in October 2002, the consortium set September 2005 as the target for completing its map of common patterns of human genetic variation, also known as haplotypes. By the end of February 2005, however, the group already will have reached completion of its first draft of the human haplotype map, or HapMap, which will consist of 1 million markers of genetic variation, called single nucleotide polymorphisms (SNPs).

The consortium's new goal is to build an improved version of the HapMap that is about five times denser than the original plan. This "Phase II" HapMap will take advantage of the rapid, high-throughput genotyping capacity of Perlegen Sciences, Inc., of Mountain View, Calif., to test another 4.6 million SNPs from publicly available databases, and add that information to the map. As a result of a grant competition last summer, Perlegen received a $6.1 million award from the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), to add data on 2.25 million additional SNPs to HapMap. The new development, enabled by a partnership among multiple funding sources, will expand that effort and test virtually the entire known catalog of human variation on the HapMap samples. This will increase the density of SNP "signposts" across the genome from the current average of one every 3,000 bases to about one every 600 bases.

"This will help us create a far more powerful HapMap than we ever imagined. We sincerely thank all those who are giving their time, technology and money to help turn this dream into reality. The payoff will be a better underst
'"/>

Source:NIH/National Human Genome Research Institute


Page: 1 2 3 4

Related biology news :

1. International trial of two microbicides begins
2. Solutions that reduce death of marine life reeled in by International Smart Gear Competition
3. International Team Determines Geographic Origin of Leprosy
4. International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy
5. International team analyzes human genetic variation in key immune region
6. NIH neuroscience microarray consortium launches high-throughput genotyping services
7. Autism gene identified by researchers at Yale working with a global research consortium
8. Gene expands malarias invasion options
9. MWG Biotech expands siMAX?siRNA portfolio with new scales, lengths and design tools
10. NHGRI expands effort to revolutionize sequencing technologies
11. New book expands biological classifications to account for alien life

Post Your Comments:
(Date:11/20/2009)... from the production of flax shives, and generated... related to those which engulf fields in spring, c...ggested by two studies carried out by Spanish and ...newable and Sustainable Energy Reviews . , "These...view, the production of bioethanol from two, as ye...
(Date:11/20/2009)... In a new study, researchers report that a class ... a helpful, or harmful, effect on the heart, depen...hich appears in the journal Circulation Research ...pha- and beta-receptors on the heart muscle offer ...that target only the beta-receptors can actually u...
(Date:11/19/2009)...utter ants, which cultivate fungus for food, have ...o add to the list: the ant farmers, like their hum...a to make their gardens grow. The finding, reporte...cuments a previously unknown symbiosis between ant...cutter ants have come to dominate the American tro...
Breaking Biology News(10 mins):Flax and yellow flowers can produce bioethanol 2Carvedilol shown to have unique characteristics among beta blockers 2Like humans, ants use bacteria to make their gardens grow 2Boston Scientific Announces Sponsorship of World Diabetes Day Campaign 2009 6132 1Boston Scientific Announces Sponsorship of World Diabetes Day Campaign 2009 6132 2Boston Scientific Announces Sponsorship of World Diabetes Day Campaign 2009 6132 3Boston Scientific Announces Sponsorship of World Diabetes Day Campaign 2009 6132 4Boston Scientific Announces Sponsorship of World Diabetes Day Campaign 2009 6132 5Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6130 1Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6130 2Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6130 3Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6130 4Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6130 5Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6130 6Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6130 7Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6130 8Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6130 9Advanced Life Sciences Announces Third Quarter 2009 Financial Results 6130 10HealthSport Inc Announces Agreement for 2410 Million Investment by SMI Manufacturing 6127 1HealthSport Inc Announces Agreement for 2410 Million Investment by SMI Manufacturing 6127 2HealthSport Inc Announces Agreement for 2410 Million Investment by SMI Manufacturing 6127 3
...ave created a new family of fluorescent probes cal...easure the presence of reactive oxygen species. Re...tes of oxygen that have been implicated in a varie...atherosclerosis. , "We,ve shown that the hydrocya...e oxygen species, superoxide and the hydroxide rad...
...gy supply based on biomass grown to generate elect...ording to Prof. Jrgen O. Metzger from Carl von Oss.... Aloys Huettermann from the University of Goettin...mical scenario, contrary to current thinking which... published online this week in Springer,s journal,...
....C. Researchers at Georgetown University Medical ...n two aggressive cancers malignant melanoma, a fo...lethal brain tumor. They add that because this gen...nactivated in several other cancers as well, their...ppressor role in a wide variety of different cance...
Other Biology News:Researchers create new class of fluorescent dyes to detect reactive oxygen species in vivo 2Researchers create new class of fluorescent dyes to detect reactive oxygen species in vivo 3Turning over a new leaf for future energy supplies 2GUMC researchers find gene function 'lost' in melanoma and glioblastoma 2GUMC researchers find gene function 'lost' in melanoma and glioblastoma 3
(Date:11/20/2009)...ov. 20 Dendreon Corporat... Food and Drug Administration (FDA) provided writt...ogics License Application (BLA) for PROVENGE®...as assigned a Prescription Drug User Fee Act (PDUF...ond to Dendreon,s amended BLA. Dendreon is seekin...
(Date:11/20/2009)... METTLER TOLEDO recently announced that Dr. Dom...o;The Role of Process Analytical Technology (PAT) ... December 1, 2009. , (PRW...rocess Analytical Technology (PAT) in Green Chemis...Process Analytical Technology (PAT) case studies w...
(Date:11/19/2009)... BETHESDA, Md., Nov. 19 ...r in biotechnology for diabetes therapy, and a pro...ces to food, supplement, biotechnology and pharmac...reviously reported $6.3 million registered direct ...shares of its common stock and warrants to purchas...
(Date:11/19/2009)...ov. 19 /PRNewswire/ - Aegera Therapeutics Inc. ann...randomized Phase 2B study of AEG35156, a targeted ... multiple oncology indications. ,, The study, e... the X-Linked Inhibitor of Apoptosis (XIAP) Antise...ytarabine and Idarubicin in AML Following Failure ...
Breaking Biology Technology:Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2
... Inc.,(Nasdaq: RDYN ) today announced its financi...ded December 31, 2007., Replidyne reported a net ... December 31, 2007, or a net loss per basic and di... a net loss of $9.6 million, or $0.36 per,basic an...mber 31, 2006.,For the year ended December 31, 200...
...utics,Inc. (Nasdaq: CVTX ) today reported financi...ded December 31, 2007., For the quarter ended Dec... $34.1 million, or $0.57 per share. This compares ..., for the same quarter in 2006 and $34.2,million, ...ptember 30,2007. For the year ended December 31, 2...
... Market Research,a global provider of pharmaceutic...as published a new report providing critical strat... a stake in the market for Rheumatoid,Arthritis (R...t Thought Leader Insight & Analysis:,Rheumatoid Ar...r Panel,debates tough questions facing drug develo...
Other Biology Technology:Replidyne Announces 2007 Fourth Quarter and Full Year Results 2Replidyne Announces 2007 Fourth Quarter and Full Year Results 3Replidyne Announces 2007 Fourth Quarter and Full Year Results 4Replidyne Announces 2007 Fourth Quarter and Full Year Results 5Replidyne Announces 2007 Fourth Quarter and Full Year Results 6Replidyne Announces 2007 Fourth Quarter and Full Year Results 7CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 2CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 4CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 5CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 6CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 7CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 8Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report 2
dotMetric Protein Assay Sample Application Tips from Upstate
Rabbit/Goat RFC1 AbVantage Pack Polyclonal Antibody, Unconjugated from Bethyl Laboratories
Bsp19 I (Nco I) from SibEnzyme
Adams Nutator Mixer (120V) from BD
Biology Products: